ArticleAJOG global reports2025
Quantifying maternal vaccination opportunities across gestational age windows: a real-world multi-country, longitudinal study.
Article in AJOG global reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review.Human vaccines & immunotherapeutics · 2026Review
- Report from the inaugural 2025 Asia-UK Maternal-Neonatal Infection and Immunity Network (AMMuNet) symposium.NPJ vaccines · 2026Article
- Article
- Timing is everything: optimizing maternal RSV immunization through ANC attendance patterns and timing in Viet Nam.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Maternal vaccination is a recognized strategy for reducing maternal and neonatal morbidity and mortality, including in low- and middle-income countries (LMICs). As new vaccines such as those for respiratory syncytial virus (RSV) and group B streptococcus (GBS) will be administered according to gestational age (GA), understanding real-world patterns of contact of pregnant women with antenatal care services (ANC) across pregnancy is essential to inform the most effective delivery strategies. Methods: We conducted a retrospective longitudinal, multisite analysis using anonymized data extracted from maternal health registers at ANC and delivery clinics in 6 LMICs: Bangladesh, The Gambia, Nepal, Nigeria, Tanzania, and Uganda. Eligible clinics contributed data from ANC and delivery services and access to routine data from January 2019 to December 2022. Retrospective, individual-level ANC attendance data from a total of 123,867 individuals were included in the study. These included the total number of ANC attendances per woman and GA at first and last ANC contact. The GA determination practices of each clinic were also recorded. Results: Across all sites, women had a median of 4 ANC contacts per pregnancy (IQR 2-5). An estimated 79·2% of women had at least one ANC contact during the 24-36-week GA window, falling to 66·6% in a 28-36 week GA window, and 46·5% at 32-36 weeks. When stratified by ANC contact frequency, the proportion with at least one contact in 24-36 weeks increased to 94·1% among women with ≥4 ANC contacts, indicating significantly greater vaccine delivery potential among those with more frequent ANC contacts. Conclusion: In these LMIC settings, the 24-36-week GA window presents opportunity for delivering maternal vaccination at high coverage. These findings underscore the need to align maternal vaccine delivery strategies with real-world ANC patterns to ensure equitable and timely vaccine access in LMICs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.